Nuvera Biosciences

Nuvera Biosciences was a molecular diagnostics company dedicated to developing gene expression-based tests for personalized cancer treatment. The company's lead programs focused on breast cancer, specifically predicting patient response to chemotherapy and endocrine therapies to guide clinical decision-making. Utilizing a proprietary bioinformatics platform, Nuvera identified multi-gene signatures that correlated with clinical outcomes. In 2011, the company was acquired by Veracyte, which integrated Nuvera's technology to expand its own portfolio of genomic diagnostic tests. The acquisition aimed to leverage Nuvera's validated signatures to improve patient care in oncology.